Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing

被引:367
作者
Fusar-Poli, Paolo [1 ,2 ]
Crippa, Jose A. [1 ,3 ]
Bhattacharyya, Sagnik [1 ]
Borgwardt, Stefan J. [1 ,4 ]
Allen, Paul [1 ]
Martin-Santos, Rocio [1 ]
Seal, Marc [1 ,5 ]
Surguladze, Simon A.
O'Carrol, Colin [1 ]
Atakan, Zerrin [1 ]
Zuardi, Antonio W. [3 ]
McGuire, Philip K. [1 ]
机构
[1] Kings Coll London, Inst Psychiat, Neuroimaging Sect, Div Psychol Med, London SE5 8AF, England
[2] Univ Pavia, Dept Appl & Psychobehav Hlth Sci, I-27100 Pavia, Italy
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Neurol Psychiat & Med Psychol, Sao Paulo, Brazil
[4] Univ Basel Hosp, Psychiat Outpatient Dept, CH-4031 Basel, Switzerland
[5] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
CEREBRAL-BLOOD-FLOW; FACIAL EXPRESSIONS; HUMAN AMYGDALA; MARIJUANA USE; BRAIN; ANXIETY; FEAR; CINGULATE; RESPONSES; CANNABINOIDS;
D O I
10.1001/archgenpsychiatry.2008.519
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Context: Cannabis use can both increase and reduce anxiety in humans. The neurophysiological substrates of these effects are unknown. Objective: To investigate the effects of 2 main psycho-active constituents of Cannabis sativa (Delta 9-tetrahydrocannabinol [Delta 9-THC] and cannabidiol [CBD]) on regional brain function during emotional processing. Design: Subjects were studied on 3 separate occasions using an event-related functional magnetic resonance imaging paradigm while viewing faces that implicitly elicited different levels of anxiety. Each scanning session was preceded by the ingestion of either 10 mg of Delta 9-THC, 600 mg of CBD, or a placebo in a double-blind, randomized, placebo-controlled design. Participants: Fifteen healthy, English-native, right-handed men who had used cannabis 15 times or less in their life. Main Outcome Measures: Regional brain activation (blood oxygenation level-dependent response), electrodermal activity (skin conductance response [SCR]), and objective and subjective ratings of anxiety. Results: Delta 9-Tetrahydrocannabinol increased anxiety, as well as levels of intoxication, sedation, and psychotic symptoms, whereas there was a trend for a reduction in anxiety following administration of CBD. The number of SCR fluctuations during the processing of intensely fearful faces increased following administration of Delta 9-THC but decreased following administration of CBD. Cannabidiol attenuated the blood oxygenation level dependent signal in the amygdala and the anterior and posterior cingulate cortex while subjects were processing intensely fearful faces, and its suppression of the amygdalar and anterior cingulate responses was correlated with the concurrent reduction in SCR fluctuations. Delta 9-Tetrahydrocannabinol mainly modulated activation in frontal and parietal areas. Conclusions: Delta 9-Tetrahydrocannabinol and CBD had clearly distinct effects on the neural, electrodermal, and symptomatic response to fearful faces. The effects of CBD on activation in limbic and paralimbic regions may contribute to its ability to reduce autonomic arousal and subjective anxiety, whereas the anxiogenic effects of Delta 9-THC may be related to effects in other brain regions.
引用
收藏
页码:95 / 105
页数:11
相关论文
共 106 条
[1]   IMPAIRED RECOGNITION OF EMOTION IN FACIAL EXPRESSIONS FOLLOWING BILATERAL DAMAGE TO THE HUMAN AMYGDALA [J].
ADOLPHS, R ;
TRANEL, D ;
DAMASIO, H ;
DAMASIO, A .
NATURE, 1994, 372 (6507) :669-672
[2]   Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence [J].
Agosti, V ;
Nunes, E ;
Levin, F .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2002, 28 (04) :645-654
[3]   Pharmacology and effects of cannabis: a brief review [J].
Ashton, CH .
BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 :101-106
[4]   Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol [J].
Berrendero, F ;
Maldonado, R .
PSYCHOPHARMACOLOGY, 2002, 163 (01) :111-117
[5]   Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide [J].
Bisogno, T ;
Hanus, L ;
De Petrocellis, L ;
Tchilibon, S ;
Ponde, DE ;
Brandi, I ;
Moriello, AS ;
Davis, JB ;
Mechoulam, R ;
Di Marzo, V .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) :845-852
[6]   Dissociable neural responses to facial expressions of sadness and anger [J].
Blair, RJR ;
Morris, JS ;
Frith, CD ;
Perrett, DI ;
Dolan, RJ .
BRAIN, 1999, 122 :883-893
[7]   Cerebellar hypoactivity in frequent marijuana users [J].
Block, RI ;
O'Leary, DS ;
Hichwa, RD ;
Augustinack, JC ;
Ponto, LLB ;
Ghoneim, MM ;
Arndt, S ;
Ehrhardt, JC ;
Hurtig, RR ;
Watkins, GL ;
Hall, JA ;
Nathan, PE ;
Andreasen, NC .
NEUROREPORT, 2000, 11 (04) :749-753
[8]   Marijuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers [J].
Bonn-Miller, Marcel O. ;
Zvolensky, Michael J. ;
Bernstein, Amit .
ADDICTIVE BEHAVIORS, 2007, 32 (01) :49-62
[9]   5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats [J].
Braida, Daniela ;
Limonta, Valeria ;
Malabarba, Lorenzo ;
Zani, Alessia ;
Sala, Mariaelvina .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 555 (2-3) :156-163
[10]   Response and habituation of the human amygdala during visual processing of facial expression [J].
Breiter, HC ;
Etcoff, NL ;
Whalen, PJ ;
Kennedy, WA ;
Rauch, SL ;
Buckner, RL ;
Strauss, MM ;
Hyman, SE ;
Rosen, BR .
NEURON, 1996, 17 (05) :875-887